Splashy headlines about psilocybin and LSD often outpace the science. Here’s how to read studies critically—and what that means for DMV drug policy conversations.

From classic rock icons to modern hip‑hop and electronic producers, these artists show how psychedelic experiences keep shaping music’s sound—and our listening habits.

The psychonaut comic brings a two-part, art-drenched special to life at Meow Wolf Denver. Here’s what to know about TRIPS, why he calls LSD “boring,” and what DMV audiences should watch for.

UCSF neuroscientist Robin Carhart-Harris uses brain imaging and clinical trials to explore how psychedelics alter cognition and mood — and what that could mean for patients in the DMV.

Exploring the science behind messianic experiences on psychedelics, clinical findings, and safe integration for DMV wellness seekers.

Athletes report flow, less pain, and sharper focus on mushrooms, LSD, and ketamine—but the science is thin. Here’s what research suggests, key risks, and DMV-specific guidance.

The Family Acid archivist reflects on a life reshaped by LSD, Vietnam, reggae, and art—plus what this cultural history means for Virginia and the wider DMV today.

New research suggests festivals and ceremonial settings may nurture similar trauma relief through community and shared meaning—raising practical lessons for DMV readers.

A close look at new research on psychedelics, authoritarian attitudes, and what an April executive action could mean—plus why DMV cannabis rules are a separate lane.

A science-forward explainer on cross-tolerance between LSD and DOI, how repeat dosing can blunt effects, and what careful timing means for patients and clinicians.

Definium Therapeutics reports Phase 3 topline success for LSD (DT120) in generalized anxiety disorder, following MDD progress. Here’s the clinical context and what DMV patients should watch.

A deep dive into new preclinical evidence linking LSD’s pro-social effects with hippocampal endocannabinoid changes and the gut microbiome—and why DMV patients should care.

An Emory-led consortium is recruiting 800 adults in the US, Canada, and Australia for a first-of-its-kind study on difficulties that persist after psychedelic experiences.